News & Updates

Use of antipsychotics, particularly long-acting injectables, results in nearly 30‒50-percent reduced risk of work disability among individuals with first-episode nonaffective psychosis compared with nonuse, a study has shown. This benefit persists beyond 5 years after first diagnosis.

Several barriers and facilitators indicate the need to create work environments where safety is a priority for the handling of antineoplastic drugs, suggests a Canada study.

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

The use of high-dose erythropoietin in the treatment of preterm infants with intraventricular haemorrhage (IVH) does not appear to produce improvements in neurological outcomes, according to a study.

Using a real-time potassium monitoring device saves money and improves quality of life (QoL) in haemodialysis patients in a study presented at Kidney Week 2022.

Treatment with rituximab appears to confer protective effects against long-term cardiovascular and metabolic outcomes in patients with pemphigus as compared with conventional immunosuppressants, according to a study.